Literature DB >> 7674237

Methotrexate in severe ankylosing spondylitis: an open study.

M C Creemers1, M J Franssen, L B van de Putte, F W Gribnau, P L van Riel.   

Abstract

OBJECTIVE: To study the efficacy and toxicity of methotrexate (MTX) for patients with ankylosing spondylitis (AS) in a 36 week, open, single observer study.
METHODS: Patients were selected for study if they had evidence of active disease and had failed to respond to treatment with nonsteroidal antiinflammatory drugs (NSAID) and sulfasalazine. Eleven patients entered the study, and 9 were evaluated at the end. Oral MTX (7.5-15 mg weekly) was given for at least 24 weeks; NSAID were kept at a stable dose. Efficacy was evaluated by calculating the relative difference of assessed variable between Week 0 and 24 and by patient evaluation.
RESULTS: Assessed variables showed good relative improvement. Four patients decided to continue MTX; 3 used a lower dose of NSAID; one stopped NSAID: Five patient patients discontinued MTX: 3 of these had disease flares and restarted MTX. Side effects were mild and reversible.
CONCLUSION: Results of our study showed that the majority of our patients with AS taking MTX had beneficial effects.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7674237

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  11 in total

Review 1.  Spondylarthropathies: options for combination therapy.

Authors:  A M van Tubergen; R B Landewé; S van der Linden
Journal:  Springer Semin Immunopathol       Date:  2001

Review 2.  New treatment options in ankylosing spondylitis: a role for anti-TNFalpha therapy.

Authors:  J Sieper; J Braun
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

Review 3.  Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease.

Authors:  Jurij Hanzel; Christopher Ma; Niels Vande Casteele; Reena Khanna; Vipul Jairath; Brian G Feagan
Journal:  Drugs       Date:  2021-01-05       Impact factor: 9.546

Review 4.  Late-onset ankylosing spondylitis and related spondylarthropathies: clinical and radiological characteristics and pharmacological treatment options.

Authors:  Eric Toussirot; Daniel Wendling
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

5.  TNFα blockers followed by continuation of sulfasalazine and methotrexate combination: a retrospective study on cost saving options of treatment in Spondyloarthritis.

Authors:  Aswin M Nair; P Sandhya; Bijesh Yadav; Debashish Danda
Journal:  Clin Rheumatol       Date:  2017-06-23       Impact factor: 2.980

Review 6.  Current guidelines for the drug treatment of ankylosing spondylitis.

Authors:  E Toussirot; D Wendling
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

Review 7.  [Biologics in the early treatment of ankylosing spondylitis and related forms of spondyloarthritis].

Authors:  Hans-Eckhard Langer
Journal:  Wien Med Wochenschr       Date:  2008

8.  Combination of methotrexate and sulfasalazine is an efficacious option for axial spondyloarthritis in a resource-limited, real-world clinical setting: a prospective cohort study.

Authors:  Arvind Ganapati; Mahasampath Gowri; Belavendra Antonisamy; Debashish Danda
Journal:  Clin Rheumatol       Date:  2020-10-14       Impact factor: 2.980

Review 9.  [Methotrexate therapy in rheumatologic diseases--an update].

Authors:  Edmund Cauza; Attila Dunky
Journal:  Wien Med Wochenschr       Date:  2003

Review 10.  Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches.

Authors:  Juergen Braun; Joachim Sieper
Journal:  Arthritis Res       Date:  2002-08-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.